Human mesenchymal stem cells as delivery of osteoprotegerin gene: homing and therapeutic effect for osteosarcoma

References

• DamronTAWardWGStewartAOsteosarcoma, chondrosarcoma, and Ewing’s sarcoma: National Cancer Data Base ReportClin Orthop Relat Res2007459404717414166
   PubMed Web of Science ®Google Scholar
• MirabelloLTroisiRJSavageSAOsteosarcoma incidence and survival rates from 1973 to 2004: data from the Surveillance, Epidemiology, and End Results ProgramCancer200911571531154319197972
   PubMed Web of Science ®Google Scholar
• SampoMKoivikkoMTaskinenMIncidence, epidemiology and treatment results of osteosarcoma in Finland – a nationwide population-based studyActa Oncol20115081206121422023116
   PubMed Web of Science ®Google Scholar
• WittrantYThéoleyreSChipoyCRANKL/RANK/OPG: new therapeutic targets in bone tumours and associated osteolysisBiochim Biophys Acta200417042495715363860
   PubMed Web of Science ®Google Scholar
• DougallWCMolecular pathways: osteoclast-dependent and osteoclast-independent roles of the RANKL/RANK/OPG pathway in tumorigenesis and metastasisClin Cancer Res201218232633522031096
   PubMed Web of Science ®Google Scholar
• MichigamiTIhara-WatanabeMYamazakiMOzonoKReceptor activator of nuclear factor kappaB ligand (RANKL) is a key molecule of osteoclast formation for bone metastasis in a newly developed model of human neuroblastomaCancer Res20016141637164411245477
   PubMed Web of Science ®Google Scholar
• TatSKPadrinesMTheoleyreSOPG/membranous – RANKL complex is internalized via the clathrin pathway before a lysosomal and a proteasomal degradationBone200639470671516750945
   PubMed Web of Science ®Google Scholar
• ChenGSircarKAprikianAPottiAGoltzmanDRabbaniSAExpression of RANKL/RANK/OPG in primary and metastatic human prostate cancer as markers of disease stage and functional regulationCancer2006107228929816752412
   PubMed Web of Science ®Google Scholar
• LamoureuxFRichardPWittrantYTherapeutic relevance of osteoprotegerin gene therapy in osteosarcoma: blockade of the vicious cycle between tumor cell proliferation and bone resorptionCancer Res200767157308731817671200
   PubMed Web of Science ®Google Scholar
• StudenyMMariniFCChamplinREZompettaCFidlerIJAndreeffMBone marrow-derived mesenchymal stem cells as vehicles for interferon-beta delivery into tumorsCancer Res200262133603360812097260
   PubMed Web of Science ®Google Scholar
• NakamizoAMariniFAmanoTHuman bone marrow-derived mesenchymal stem cells in the treatment of gliomasCancer Res20056583307331815833864
   PubMed Web of Science ®Google Scholar
• RenCKumarSChandaDCancer gene therapy using mesenchymal stem cells expressing interferon-beta in a mouse prostate cancer lung metastasis modelGene Ther200815211446145318596829
   PubMed Web of Science ®Google Scholar
• DembinskiJLWilsonSMSpaethELTumor stroma engraftment of gene-modified mesenchymal stem cells as anti-tumor therapy against ovarian cancerCytotherapy2013151203223260083
   PubMed Web of Science ®Google Scholar
• MaderEKButlerGDowdySCOptimizing patient derived mesenchymal stem cells as virus carriers for a phase I clinical trial in ovarian cancerJ Transl Med2013112023347343
   PubMed Web of Science ®Google Scholar
• HuangXZhangFWangHMesenchymal stem cell-based cell engineering with multifunctional mesoporous silica nanoparticles for tumor deliveryBiomaterials20133471772178023228423
   PubMed Web of Science ®Google Scholar
• SageEKKolluriKKMcNultyKSystemic but not topical TRAIL-expressing mesenchymal stem cells reduce tumour growth in malignant mesotheliomaThorax201469763864724567297
   PubMed Web of Science ®Google Scholar
• PetsaAGarganiSFelesakisAGrigoriadisNGrigoriadisIEffectiveness of protocol for the isolation of Wharton’s Jelly stem cells in large-scale applicationsIn Vitro Cell Dev Biol Anim2009451057357619609625
   PubMed Web of Science ®Google Scholar
• LamoureuxFPicardaGGarrigue-AntarLGlycosaminoglycans as potential regulators of osteoprotegerin therapeutic activity in osteosarcomaCancer Res200969252653619147566
   PubMed Web of Science ®Google Scholar
• LoebingerMREddaoudiADaviesDJanesSMMesenchymal stem cell delivery of TRAIL can eliminate metastatic cancerCancer Res200969104134414219435900
   PubMed Web of Science ®Google Scholar
• HessDCHillWDMartin-StuddardACarrollJBrailerJCarothersJBone marrow as a source of endothelial cells and NeuN-expressing cells after strokeStroke20023351362136811988616
   PubMed Web of Science ®Google Scholar
• OkamotoRYajimaTYamazakiMDamaged epithelia regenerated by bone marrow-derived cells in the human gastrointestinal tractNat Med2002891011101712195435
   PubMed Web of Science ®Google Scholar
• HerreraMBBussolatiBBrunoSFonsatoVRomanazziGMCamussiGMesenchymal stem cells contribute to the renal repair of acute tubular epithelial injuryInt J Mol Med20041461035104115547670
   PubMed Web of Science ®Google Scholar
• SpeesJLWhitneyMJSullivanDEBone marrow progenitor cells contribute to repair and remodeling of the lung and heart in a rat model of progressive pulmonary hypertensionFASEB J20082241226123618032636
   PubMed Web of Science ®Google Scholar
• Ben-BaruchAHost microenvironment in breast cancer development: inflammatory cells, cytokines and chemokines in breast cancer progression: reciprocal tumor-microenvironment interactionsBreast Cancer Res200351313612559043
   PubMed Web of Science ®Google Scholar
• SpaethEKloppADembinskiJAndreeffMMariniFInflammation and tumor microenvironments: defining the migratory itinerary of mesenchymal stem cellsGene Ther2008151073073818401438
   PubMed Web of Science ®Google Scholar
• ReaganMRSeibFPMcMillinDWStem cell implants for cancer therapy: TRAIL-expressing mesenchymal stem cells target cancer cells in situJ Breast Cancer201215327328223091539
   PubMed Web of Science ®Google Scholar
• KarpJMLeng TeoGSMesenchymal stem cell homing: the devil is in the detailsCell Stem Cell20094320621619265660
   PubMed Web of Science ®Google Scholar
• KeanTJLinPCaplanAIDennisJEMSCs: delivery routes and engraftment, cell-targeting strategies, and immune modulationStem Cells Int2013201373274224000286
   PubMed Web of Science ®Google Scholar
• AkiyamaTDassCRChoongPFNovel therapeutic strategy for osteosarcoma targeting osteoclast differentiation, bone-resorbing activity, and apoptosis pathwayMol Cancer Ther20087113461346919001431
   PubMed Web of Science ®Google Scholar
• LeeJAJungJSKimDHRANKL expression is related to treatment outcome of patients with localized, high-grade osteosarcomaPediatr Blood Cancer201156573874321370405
   PubMed Web of Science ®Google Scholar
• LamoureuxFPicardaGRousseauJTherapeutic efficacy of soluble receptor activator of nuclear factor-kappa B-Fc delivered by nonviral gene transfer in a mouse model of osteolytic osteosarcomaMol Cancer Ther20087103389339818852142
   PubMed Web of Science ®Google Scholar
• ZhangJDaiJQiYOsteoprotegerin inhibits prostate cancer-induced osteoclastogenesis and prevents prostate tumor growth in the boneJ Clin Invest2001107101235124411375413
   PubMed Web of Science ®Google Scholar
• BodyJJGreippPColemanREA phase I study of AMGN-0007, a recombinant osteoprotegerin construct, in patients with multiple myeloma or breast carcinoma related bone metastasesCancer2003973 Suppl88789212548591
   PubMed Web of Science ®Google Scholar
• DougallWCGlaccumMCharrierKRANK is essential for osteoclast and lymph node developmentGenes Dev199913182412242410500098
   PubMed Web of Science ®Google Scholar
• KongYYFeigeUSarosiIActivated T-cells regulate bone loss and joint destruction in adjuvant arthritis through osteoprotegerin ligandNature1999402675930430910580503
   PubMed Web of Science ®Google Scholar